Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Pharma Sector Turns to Chronic Lifestyle Disorders (India)

This article was originally published in PharmAsia News

Executive Summary

Indian pharmaceutical companies are now turning to diabetes, arthritis, and other diseases of the developed world. The sector has re-oriented its research and development priorities from infectious diseases found in the under-developed world to chronic lifestyle disorders that threaten the developed world. The first possible product patent to be handed out after the patent regime changed in 2005 is likely to belong to the anti-chronic segment. Dr Reddy's Laboratory announced recently the beginning of phase III clinical trials of its anti-diabetic drug balagliatzone. Co-developed with Danish firm Rheoscience, the successful completion of the trial could give India its first intellectual property from the pharma sector. Sujay Shetty, associate director (pharmaceutical and life sciences), at PricewaterhouseCoopers, says, "Big pharma companies in the country are shifting R&D to focus on developing drugs to fight chronic illnesses. The move is apparent from the ongoing research of new chemical entities, especially in companies like Glenmark and Torrent pharmaceuticals." While deaths from infectious diseases and other deficiencies in India are estimated to decrease by 15 percent in the next ten years, according to the World Health Organization, the figure for chronic diseases is expected to grow by 18 percent with diabetes alone witnessing a 35 percent growth. D G Shah, secretary general of the Indian Pharmaceutical Alliance, concedes that the market for chronic disease drugs is still very small in India. "But," he adds, "If we look at the current pipeline, there is a general perception that cardiovascular and diabetes are research areas where some companies are focusing, though there are no numbers to support this." (Click here for more

You may also be interested in...



Re-Wiring US FDA’s Regulatory Thinking

The efforts to upgrade FDA’s information technology infrastructure may be opening up into an opportunity to reinvent its processes for regulatory decision making.

Congressional Democrats Press US FDA For Transparency In Review Of COVID-19 Vaccines

FDA should have all coronavirus vaccines evaluated by Vaccines and Related Biological Products Advisory Committee before approval, Democratic senators and representatives say; House subcommittee also wants FDA to require 30,000 participants in Phase III trials.

Flutter Over Biocon’s Repurposed Psoriasis Drug For COVID-19 In India

Biocon’s itolizumab gets clearance in India for restricted emergency use in COVID-19 patients, amid some concerns around small study numbers. But company says data are compelling and cites compassionate use substantiation, while partner Equillium expects to pursue a global study under US IND.

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel